- MedTech company Outset Medical ( NASDAQ: OM ) stretched the post-earnings rally to the third straight session on Friday after RBC Capital Markets launched its coverage with an Outperform recommendation pointing to its undervaluation.
- Outset Medical ( OM ), which develops a hemodialysis system, has lost ~64% over the past 12 months, underperforming its peers in the dialysis market, such as DaVita ( DVA ), Fresenius Medical Care ( FMS ) as indicated in this graph.
- RBC analysts led by Shagun Singh think that Outset Medical ( OM ), which offers technology to lower the cost and complexity of dialysis, has the potential to cater to an $11B total addressable market for kidney failure in the U.S.
- “In our view, OM is significantly undervalued given the opportunities ahead,” the team wrote, issuing a $23 per share target on the stock.
- Thanks to industry tailwinds such as the shift to home care aided by reimbursements, Outset Medical ( OM ) is positioned to generate 46% and 39% CAGR for 3-year and 5-year periods, the best in MedTech, the analysts added.
- With its Q3 2022 financials on Tuesday, Outset Medical ( OM ) topped Street estimates and raised its full-year outlook.
For further details see:
Outset Medical extends gains as RBC Capital Markets initiates at Outperform